CDC: Monovalent Vax Has ‘Limited’ Protection Against BA.4/5 Hospitalization

A monovalent mRNA booster dose offered “limited” protection against COVID-related hospitalizations from the currently circulating Omicron variants, a CDC analysis found, likely due to the waning effects of the vaccines and potentially more immune evasion with BA.4/BA.5.

In immunocompetent adults, vaccine effectiveness (VE) against hospitalization with three doses of mRNA vaccine dropped from 69% (95% CI 62-74) during the BA.1/BA.2 period to 31% (95% CI 7-49) during BA.4/BA.5, reported Diya Surie, MD, of CDC’s COVID-19 Emergency Response Team, and colleagues.

During the period of BA.4/BA.5 specifically, protection against hospitalization declined from 60% (95% CI 12-81) in the first 4 months from the third dose to 29% (95% CI 3-48) thereafter, according to their findings in the Morbidity and Mortality Weekly Report (MMWR).

A second study, also published in MMWR, showed similar declines for individuals with immunocompromising conditions during the period of Omicron predominance. VE against COVID-related hospitalizations with three doses was 67% (95% CI 63-71) during the BA.1 period in this population, which fell to 32% (95% CI 22-42) during periods of BA.2/BA.2.12.1 and BA.4/BA.5 circulation, according to researchers led by Amadea Britton, MD, also of the CDC’s COVID-19 Emergency Response Team.

A fourth dose appeared to restore some of the protection in these immunocompromised individuals during the periods of BA.2/BA.2.12.1 and BA.4/BA.5 circulation, with VE landing at 43% (95% CI 27-56) with the additional dose.

Researchers from both studies argued that the findings demonstrate the importance of staying up to date with COVID-19 vaccinations and suggested that the newer bivalent mRNA shots may offer superior protection, given that they target circulating BA.4/BA.5 sublineages, as well as the ancestral strain of SARS-CoV-2.

Read Full Story
Medpage Today Rating

Left vs. Right Bias: How we rate the bias of media sources

Subscribe With Email

Enter your email address to subscribe to MBFC and receive notifications of new posts by email.

Join 22,513 other subscribers

Be the first to comment on "CDC: Monovalent Vax Has ‘Limited’ Protection Against BA.4/5 Hospitalization"


This site uses Akismet to reduce spam. Learn how your comment data is processed.